medigraphic.com
ISSN 1561-2988 (Print)

2015, Number 3

<< Back Next >>

Rev Cubana Farm 2015; 49 (3)

Progression of patients with alcohol dependence using acamprosate

Martínez MG, Galán ML, Flores BI

Language: Spanish
References: 23
Page: 462-472
PDF size: 106.29 Kb.


ABSTRACT

Introduction: the effects of the excessive intake of alcohol beverages for the individual, the family and the society represent a health problem turned into the most transcendental toxicomania at present times. There are three drugs on the market which reduce the desire of drinking and are called disulfiram, naltrexone and acamprosate. The latter is the drug to be studied since there are no previous references in Cuba about effectiveness study of acamprosate.
Objective: to assess the progression of alcoholism and its treatment with acamprosate.
Methods: adescriptive and observational Study of Drug Use was designed on the basis of the practical consequences of the use of acamprosate in patients diagnosed with alcohol dependence, at a dose of two caplets of 33.3mg to be taken daily for six months from September 2012 to February 2013.
Results: of 44 evaluated patients, 90.9% had no relapses, just 9.1% felt the desire of taking alcohol beverages at the onset of treatment. One patient showed restlessness as adverse effect of the drug. The self-assessment of all the patients was positive, stating that they changed into a better person after treatment. In the group, 68.2% had an excellent progress which agrees with other international study on this drug.
Conclusions: the treatment with acamprosate is effective for the prevention of relapses and the reduction of alcohol dependence.


REFERENCES

  1. González R. Misión: Rescate de adictos. Guía para la relación de ayuda con toxicómanos. La Habana: Ediciones Abril; 2012.

  2. González R. El alcoholismo y su atención específica. La Habana: Editorial Ciencias Médicas; 1992.

  3. Popova S, Mohapatra S, Patra J, Duhig A, Rehm J. A Literature Review of Cost- Benefit Analyses for the Treatment of Alcohol Dependence. Int. J Environ Res Public Health. 2011; 8: 3351-3364.

  4. González R. Cómo enfrentar el peligro de las drogas. Santiago de Cuba: Editorial Oriente; 2000.

  5. Skinner M, Lahmek P, Pham H, Aubin H. Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis. PLoS One. 2014; 9(2): e87366.

  6. Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol. 2006; 44: 791–797.

  7. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013; 108(2): 275-293.

  8. Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014 Feb; 77 (2): 315-23.

  9. Jaurigue MM and Cappell MS. Therapy for alcoholic liver disease. World J Gastroenterol. 2014 Mar 7; 20(9): 2143–2158.

  10. Joseph R, Yancey M and Jaydee L. Opioid Antagonists for the Treatment of Alcohol Dependence. Am Fam Physician. 2011; 84(9): 990-992.

  11. Bankole A and Phil M. UPDATE ON NEUROPHARMACOLOGICAL TREATMENTS FOR ALCOHOLISM: SCIENTIFIC BASIS AND CLINICAL FINDINGS. Biochem Pharmacol. 2008; 75(1): 34–56.

  12. Franklin J and Frances R. Trastornos por consumo de alcohol y de otras sustancias psicoactivas. En: Hales de R, Yudovsky S y Talbot JU. DSM-IV Tratado de Psiquiatría. 3ra. Edición. Madrid: Editorial Masson; 2000.

  13. MINSAP. Tercer Glosario Cubano de Psiquiatría. La Habana: Editorial Ciencias Médicas; 2008.

  14. Williams SH. Medications for Treating Alcohol Dependence. Am Fam Physician. 2005 Nov 1; 72(9): 1775-1780.

  15. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001; 62 (suppl. 20): 42–8.

  16. Mason BJ, Heyser CJ. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf. 2010; 9(1):177–188.

  17. Bouza C, Angeles M, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004; 99: 811–828.

  18. Ministerio de Salud Pública. Centro para el Desarrollo de la Farmacoepidemiología. Formulario Nacional de Medicamentos. La Habana: Editorial Ciencias Médicas; 2011.

  19. Witkiewitz K, Saville K, Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Therapeutics and Clinical Risk Management. 2012; 8: 45–53.

  20. Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, et al. Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism. Am J Psychiatry. 2014; Apr 1; 171(4): 445-52.

  21. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014 Jan; 174(1): 70-7.

  22. Franck J, Jayaram-Lindström N. Pharmacotherapy for alcohol dependence: status of current treatments. Curr Opin Neurobiol. 2013; Aug; 23(4): 692-9.

  23. Collins GB, McAllister MS, Adury K. Drug adjuncts for treating alcohol dependence. Cleveland Clinic Journal of Medicine. 2006; 73 (7): 641-656.




2020     |     www.medigraphic.com